TNXP Tonix Pharmaceuticals Holding Corp. Insider Trading

Director Richard Newcomb Stillwell buys 5,000 shares of TNXP at $11.65; stock down -83.6% from 52-week high amid unprofitable operations.

Richard Newcomb Stillwell, a director at Tonix Pharmaceuticals, purchased 5,000 shares at $11.65 on 2026-06-08, establishing a position in a company currently trading at $11.46—83.6% below its 52-week high of $69.97. The company generated $6.9M in quarterly revenue but posted a net loss of $40.2M, indicating significant burn relative to sales despite 29.8% annual revenue growth. The stock has declined 18.7% over 30 days and 18.0% over 90 days, reflecting sustained pressure on the equity. This purchase by a director during a period of substantial price deterioration occurs in the context of an unprofitable operation and warrants examination of the director's historical transaction pattern and the company's path to profitability.

CEO Seth Lederman buys 5,000 TNXP shares at $11.79; stock down 83.6% from $69.97 high, now at $11.46.

Seth Lederman, Chief Executive Officer, purchased 5,000 shares at $11.79 on 2026-06-09, increasing his holdings by 124.8% from 4,005 to 9,005 shares. The purchase occurs with the stock trading at $11.46, down 83.6% from its 52-week high of $69.97 and declined 18.7% over the prior 30 days. At Tonix Pharmaceuticals, Lederman's three prior open-market purchases show mixed results: one trade posted +48.4% 30-day and +185.7% 90-day returns (2025-05-15), while the two most recent buys (March 2026) delivered negative 30-day and 90-day returns, with the latest showing -6.1% and -21.4% respectively. The company remains unprofitable with a net loss of $40.2M in the latest full fiscal year, though annual revenue grew 29.8% year-over-year to $6.9M in the most recent quarter. This purchase at a depressed absolute price level follows a steep recent drawdown and occurs amid unprofitable operations, warranting analysis of whether the CEO's conviction translates to shareholder value recovery.